about
Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomesLysosome-endosome fusion and lysosome biogenesis.Stage at diagnosis and early mortality from cancer in England.Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006-2009Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experimentsSocio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer.Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR).Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes.Non-endoscopic immunocytological screening test for Barrett's oesophagus.Vulval cancer incidence, mortality and survival in England: age-related trends.A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposalTNM clinical staging of prostate cancer: Issues and solutionsMyxofibrosarcomas contain large numbers of infiltrating immature dendritic cellsMisinterpretation of the origins and composition of staging data and its impact on colorectal cancer survivalTowards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnosesExploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based studyPancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based studyGlobal trends in mortality from intrahepatic and extrahepatic cholangiocarcinomaImpact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsiesData Resource Profile: National Cancer Registration Dataset in EnglandGlobal Consultation on Cancer Staging: promoting consistent understanding and useData Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer ReportingPractical Guidance for Measuring and Reporting Surgical Margins in Vulvar CancerNationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in EnglandHistological groups
P50
Q24548353-E89A8F20-CE4E-497A-9485-A0E64FD02A52Q33883540-854AC786-5724-4606-90CA-096A49C91451Q35275282-10C6F463-2712-492C-9604-8F8A6B947222Q35832289-1ECC0CFE-5769-4058-BF2A-34BE05ABA8B4Q35873739-E512D9D6-2406-4C84-BCD4-F1C344BC7AC1Q36615776-C1CD8D49-7F1C-4668-B3A3-718C29D4EF63Q38682502-CFC0BD53-C6EA-42FB-BAE4-E93388334BF3Q40960406-10202F95-14DF-48D4-9B96-46930FE3B8B1Q42339785-C82966DC-F66E-465C-AE6E-500F3C7E625FQ42447020-7707D22C-A858-4482-ADF7-A670CA3121A2Q56341375-578EED4A-AC96-4308-9045-2D7B6042336AQ57468119-46330526-D96D-4E5A-ADA0-89FD08D10483Q73306295-91D3BE78-A49B-47EC-AEAA-6AB8064635BEQ87119957-6A5DB4BE-F036-4DAF-B7B2-159AA3177104Q87446000-20B235E7-1BE2-4CE5-83FE-CB259685904AQ89473121-B0801110-A293-47B2-B19C-117B5B66C516Q89515353-FE8126D0-0AB1-42C2-B34D-E151F9792D0DQ90314299-3AD9BFCD-0B8D-4B57-93A7-4E43BE3E7E7CQ90929835-FA596893-9128-46B6-BDE7-402A17E8A2A2Q91911967-D6328231-2B91-4628-9ACB-9B15D9A9A372Q92236106-3E9289D8-EEF8-4CCC-901C-3E40545A66ADQ92461131-6B44B53C-F149-4898-87B5-537F390FF208Q92896490-49D09994-E655-4D6A-89E9-6D5DF296E226Q92952947-06E21C28-9645-40C0-BA1B-6C8283AD6456Q93365345-8D194B6F-325D-431D-A237-D7B29BAF1F44Q95376183-8D411885-6B4C-4A64-8321-D8128BEEDDC7
P50
description
researcher
@en
name
Brian Rous
@en
Brian Rous
@nl
type
label
Brian Rous
@en
Brian Rous
@nl
altLabel
B A Rous
@en
prefLabel
Brian Rous
@en
Brian Rous
@nl
P106
P31
P496
0000-0002-7619-461X